Greenwich LifeSciences (GLSI) announced the activation of clinical sites in France. The Company has partnered with Unicancer and its breast cancer group. The FLAMINGO-01 study will be activated in approximately 19 French sites in the UCBG network. These sites were approved by French authorities in Q1 2024, which led to site initiation visits and training of 15 sites in Q2-Q4 of 2024, with the remaining 4 sites scheduled for start-up activities in Q1-Q2 of 2025.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI: